OKYO Pharma Limited (OKYO) 10-Year Financial Performance & Capital Metrics

OKYO • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesOphthalmology & Ocular Diseases

AboutOKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.Show more

Revenue $0
EBITDA -$7M +54.2%
Net Income -$5M +72.0%
EPS (Diluted) -0.12 -19900.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -8.14 +45.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 34.6% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM18.13%

EPS CAGR

10Y-

5Y-

3Y-

TTM0.08%

ROCE

10Y Avg-996.84%

5Y Avg-1077.89%

3Y Avg-2927.26%

Latest-

Peer Comparison

Ophthalmology & Ocular Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KPRXKiora Pharmaceuticals, Inc.	8.05M	2.19	2.52		22.47%	-38.12%	100%	0.00
KALAKALA BIO, Inc.	16.74M	0.60	-0.09		-141.11%	-388.29%		2.62
CLSDClearside Biomedical, Inc.	5.81M	1.11	-0.16	-79.77%	-7.81%
OTLKOutlook Therapeutics, Inc.	33.47M	0.52	-0.29		-25.93%
ADVMAdverum Biotechnologies, Inc.	96.26M	4.36	-0.66	-72.22%	-130.93%	-189.84%		1.30
IRDOpus Genetics, Inc.	143.45M	2.08	-0.97	-42.3%	-466.09%	-11.43%
SKYESkye Bioscience, Inc.	30.87M	0.96	-1.32			-156.01%		0.01
ALDXAldeyra Therapeutics, Inc.	265.32M	4.41	-4.69			-87.71%		0.22

Profit & Loss

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	219	5.97K	13.09K	2.42K	3.8K	3.87K	2.56K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	-219	-5.97K	-13.09K	-2.42K	-3.8K	-3.87K	-2.56K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-26.26%	-1.19%	0.81%	-0.57%	-0.02%	0.34%
Operating Expenses+	1.1M	363.27K	985.82K	4.54M	1.51M	3.37M	6.22M	6.34M	15.69M	7.19M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	1.05M	363.2K	573.43K	1.85M	995.42K	2.97M	4.93M	6.75M	7.45M	4.93M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	0	0	0	3.04M	517.46K	348.35K	1.61M	6.34M	8.24M	2.25M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	48.57K	0	-12.43K	-15.81K	0	43.65K	-320K	-6.75M	0	0
Operating Income+	-1.1M	-363K	-28.29M	-4.54M	-1.52M	-4.13M	-6.23M	-13.09M	-15.69M	-7.19M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	0.37%	0.67%	-76.92%	0.84%	0.67%	-1.72%	-0.51%	-1.1%	-0.2%	0.54%
EBITDA+	-1.12M	-310.48K	76.32M	-4.54M	-1.51M	-4.12M	-6.23M	-13.08M	-15.69M	-7.19M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-1.25%	0.72%	246.81%	-1.06%	0.67%	-1.72%	-0.51%	-1.1%	-0.2%	0.54%
D&A (Non-Cash Add-back)	-18.71K	52.52K	104.61M	218	5.97K	13.11K	2.33K	3.8K	3.87K	2.56K
EBIT	-1.06M	-365K	0	-4.53M	-1.5M	-3.37M	-6.22M	-13.19M	-15.75M	-7.09M
Net Interest Income+	0	0	0	0	46.91K	-1.12K	0	-96.69K	-1.05M	-878.17K
Interest Income	12.36K	4.42K	0	0	48.06K	0	0	0	0	5.47K
Interest Expense	0	0	0	0	1.16K	1.12K	0	96.69K	1.05M	883.65K
Other Income/Expense	96K	121.34K	-12.44K	-363K	-99.49K	754.85K	0	-196.62K	-1.11M	-781.2K
Pretax Income+	-1.01M	-242K	-28.27M	-4.9M	-1.62M	-3.38M	-6.22M	-13.28M	-16.8M	-7.97M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-190K	0	0	0	-76.19K	-24.99K	-787K	-12.2K	22.41K	-3.26M
Effective Tax Rate %	0.81%	1%	1%	1%	0.95%	0.99%	0.87%	1%	1%	0.59%
Net Income+	-820K	-243K	-28.3M	-4.89M	-1.54M	-3.35M	-5.43M	-13.27M	-16.83M	-4.71M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	0.9%	0.7%	-115.46%	0.83%	0.68%	-1.17%	-0.62%	-1.44%	-0.27%	0.72%
Net Income (Continuing)	-820K	-242K	-28.27M	-4.9M	-1.54M	-3.35M	-5.43M	-13.27M	-16.83M	-4.71M
Discontinued Operations	190.41K	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.14	-0.04	-4.80	-0.62	-0.17	-0.32	-0.36	-0.60	-0.00	-0.12
EPS Growth %	0.89%	0.7%	-115.22%	0.87%	0.73%	-0.88%	-0.13%	-0.67%	1%	-
EPS (Basic)	-0.17	-0.04	-4.80	-0.62	-0.17	-0.32	-0.36	-0.60	-0.00	-0.12
Diluted Shares Outstanding	5.86M	5.86M	5.89M	7.91M	9.16M	10.35M	15.06M	22.26M	29.34M	39.49M
Basic Shares Outstanding	4.76M	5.86M	5.89M	7.91M	9.16M	10.35M	15.06M	22.26M	29.34M	39.49M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	5.37M	16.86M	48	758.75K	566.73K	6.99M	4.3M	5.2M	1.54M	3.68M
Cash & Short-Term Investments	5.13M	16.86M	0	627.56K	234.96K	6.89M	2.7M	4.05M	826.85K	1.56M
Cash Only	5.13M	0	0	627.56K	234.96K	6.89M	2.7M	4.05M	826.85K	1.56M
Short-Term Investments	0	16.86M	0	0	0	0	0	0	0	0
Accounts Receivable	12.15K	0	48	111.36K	326.22K	4.5K	883.43K	980.08K	580.94K	1.89M
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	126	-792	34	-1.49K	170.31K	0	0
Days Inventory Outstanding	-	-	-	209.68	-	0.95	-	16.37K	-	-
Other Current Assets	101.64K	0	0	85.46K	15	71.75K	1.49K	-170.31K	0	0
Total Non-Current Assets+	26.81M	0	0	1.1K	30.66K	104.64K	5.22K	7.22K	3.35K	2.04K
Property, Plant & Equipment	17.16M	0	0	1.1K	30.66K	104.64K	5.22K	7.22K	3.35K	2.04K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	616.71K	0	0	0	0	0	0	0	0	0
Intangible Assets	9.03M	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	0	0	0
Total Assets+	32.18M	0	0	759.86K	597.4K	7.09M	4.3M	5.2M	1.54M	3.68M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.05%	-1%	-	-	-0.21%	10.87%	-0.39%	0.21%	-0.7%	1.39%
Total Current Liabilities+	181.34K	0	0	426.72K	710.66K	1.71M	1.35M	7.26M	7.42M	9.23M
Accounts Payable	124.12K	141.79K	0	381.76K	593.72K	210.99K	517.67K	1.02M	6.13M	7.9M
Days Payables Outstanding	-	-	-	635.78K	36.29K	5.89K	77.98K	98.42K	578.57K	1000K
Short-Term Debt	0	0	0	0	0	34.14K	0	2.22M	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	16.95K	0	87.59K	-1.13K	-26.73K	1.43M	323.06K	1.29M	0	0
Current Ratio	29.62x	-	-	1.78x	0.80x	4.09x	3.17x	0.72x	0.21x	0.40x
Quick Ratio	29.62x	-	-	1.78x	0.80x	4.09x	3.18x	0.69x	0.21x	0.40x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	26.54K	64.61K	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	21.45K	64.61K	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	5.08K	0	0	0	0	0
Total Liabilities	181.34K	0	0	426.72K	737.2K	1.77M	1.35M	7.26M	7.42M	9.23M
Total Debt+	0	0	0	0	25.56K	98.76K	0	2.22M	0	0
Net Debt	-5.13M	0	0	-627.56K	-209.4K	-6.79M	-2.7M	-1.83M	-826.85K	-1.56M
Debt / Equity	-	-	-	-	-	0.02x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-1313.88x	-3680.63x	-	-135.36x	-14.90x	-8.14x
Total Equity+	32M	0	0	333.14K	-139.8K	5.32M	2.95M	-2.05M	-5.88M	-5.55M
Equity Growth %	-0.06%	-1%	-	-	-1.42%	39.05%	-0.45%	-1.7%	-1.86%	0.06%
Book Value per Share	5.46	-	-	0.04	-0.02	0.51	0.20	-0.09	-0.20	-0.14
Total Shareholders' Equity	32M	0	0	333.14K	-139.8K	5.32M	2.95M	-2.05M	-5.88M	-5.55M
Common Stock	95.12M	0	0	89.22M	0	0	123.98M	0	143.11M	0
Retained Earnings	-64.71M	0	0	-88.97M	-85.88M	-99.4M	-112.43M	-125.7M	-142.52M	-143.02M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-276.54K	0	0	82.12K	2.22M	12.82M	-11.01M	-7.74M	-11.31M	-11.47M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	-650.88K	-651.27K	-1.59M	-1.99M	-1.2M	-1.6M	-5.47M	-7.7M	-9.49M	-1.81M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	0.54%	-0%	-1.45%	-0.25%	0.4%	-0.33%	-2.42%	-0.41%	-0.23%	0.81%
Net Income	-820.17K	-241.93K	-28.27M	-4.9M	-1.62M	-3.38M	-6.22M	-13.28M	-16.83M	-7.97M
Depreciation & Amortization	0	0	0	218	5.98K	13.11K	2.33K	3.8K	3.87K	2.56K
Stock-Based Compensation	99.2K	18.37K	4.24K	50.53K	36.34K	544.39K	1.72M	1.27M	1.12M	734.99K
Deferred Taxes	0	0	0	-1.17K	146.58K	92.95K	-9.41K	250.34K	0	0
Other Non-Cash Items	-39.25K	0	26.63M	2.69M	42.84K	83K	61.72K	-84.16K	3.54M	1.8M
Working Capital Changes	109.34K	-427.71K	35.72K	176.81K	186.53K	1.04M	-1.02M	4.14M	2.67M	3.63M
Change in Receivables	0	0	0	0	-543	205.07K	27.38K	167.72K	440.26K	-90.4K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	-297.99K	0	2.8M	0
Cash from Investing+	-335.18K	-375.39K	0	-1.32K	-132.67K	-18.11K	-1.67K	-5.92K	0	-1.21K
Capital Expenditures	-406.05K	-375.39K	0	-1.32K	0	-6.94K	-1.67K	-5.92K	0	-1.21K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-334.72K	-373.6K	0	0	-132.67K	-21	0	0	0	0
Cash from Financing+	12.36K	4.42K	0	0	963.31K	7.83M	2.15M	9.32M	6.21M	2.66M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	963.31K	15.87K	725.51K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.06M	-1.03M	-1.59M	-1.99M	-1.2M	-1.61M	-5.47M	-7.7M	-9.49M	-1.81M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	0.75%	0.03%	-0.55%	-0.25%	0.4%	-0.34%	-2.4%	-0.41%	-0.23%	0.81%
FCF per Share	-0.18	-0.18	-0.27	-0.25	-0.13	-0.16	-0.36	-0.35	-0.32	-0.05
FCF Conversion (FCF/Net Income)	0.79x	2.68x	0.06x	0.41x	0.78x	0.48x	1.01x	0.58x	0.56x	0.38x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-2.49%	-	-	-1469.36%	-1595.28%	-129.51%	-131.39%	-2968.58%	-	-
Return on Invested Capital (ROIC)	-3.04%	-	-	-17587.12%	-	-	-1894.47%	-	-	-
Debt / Equity	-	-	-	-	-	0.02x	-	-	-	-
Interest Coverage	-	-	-	-	-1313.88x	-3680.63x	-	-135.36x	-14.90x	-8.14x
FCF Conversion	0.79x	2.68x	0.06x	0.41x	0.78x	0.48x	1.01x	0.58x	0.56x	0.38x

Frequently Asked Questions

Growth & Financials

OKYO Pharma Limited (OKYO) grew revenue by 0.0% over the past year. Growth has been modest.

OKYO Pharma Limited (OKYO) reported a net loss of $4.7M for fiscal year 2025.

Dividend & Returns

OKYO Pharma Limited (OKYO) had negative free cash flow of $1.8M in fiscal year 2025, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

OKYO Pharma Limited (OKYO) 10-Year Financial Performance & Capital Metrics

OKYO • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesOphthalmology & Ocular Diseases

Revenue $0
EBITDA -$7M +54.2%
Net Income -$5M +72.0%
EPS (Diluted) -0.12 -19900.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -8.14 +45.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 34.6% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM18.13%

EPS CAGR

10Y-

5Y-

3Y-

TTM0.08%

ROCE

10Y Avg-996.84%

5Y Avg-1077.89%

3Y Avg-2927.26%

Latest-

Peer Comparison

Ophthalmology & Ocular Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KPRXKiora Pharmaceuticals, Inc.	8.05M	2.19	2.52		22.47%	-38.12%	100%	0.00
KALAKALA BIO, Inc.	16.74M	0.60	-0.09		-141.11%	-388.29%		2.62
CLSDClearside Biomedical, Inc.	5.81M	1.11	-0.16	-79.77%	-7.81%
OTLKOutlook Therapeutics, Inc.	33.47M	0.52	-0.29		-25.93%
ADVMAdverum Biotechnologies, Inc.	96.26M	4.36	-0.66	-72.22%	-130.93%	-189.84%		1.30
IRDOpus Genetics, Inc.	143.45M	2.08	-0.97	-42.3%	-466.09%	-11.43%
SKYESkye Bioscience, Inc.	30.87M	0.96	-1.32			-156.01%		0.01
ALDXAldeyra Therapeutics, Inc.	265.32M	4.41	-4.69			-87.71%		0.22

Profit & Loss

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	219	5.97K	13.09K	2.42K	3.8K	3.87K	2.56K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	-219	-5.97K	-13.09K	-2.42K	-3.8K	-3.87K	-2.56K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-26.26%	-1.19%	0.81%	-0.57%	-0.02%	0.34%
Operating Expenses+	1.1M	363.27K	985.82K	4.54M	1.51M	3.37M	6.22M	6.34M	15.69M	7.19M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	1.05M	363.2K	573.43K	1.85M	995.42K	2.97M	4.93M	6.75M	7.45M	4.93M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	0	0	0	3.04M	517.46K	348.35K	1.61M	6.34M	8.24M	2.25M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	48.57K	0	-12.43K	-15.81K	0	43.65K	-320K	-6.75M	0	0
Operating Income+	-1.1M	-363K	-28.29M	-4.54M	-1.52M	-4.13M	-6.23M	-13.09M	-15.69M	-7.19M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	0.37%	0.67%	-76.92%	0.84%	0.67%	-1.72%	-0.51%	-1.1%	-0.2%	0.54%
EBITDA+	-1.12M	-310.48K	76.32M	-4.54M	-1.51M	-4.12M	-6.23M	-13.08M	-15.69M	-7.19M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-1.25%	0.72%	246.81%	-1.06%	0.67%	-1.72%	-0.51%	-1.1%	-0.2%	0.54%
D&A (Non-Cash Add-back)	-18.71K	52.52K	104.61M	218	5.97K	13.11K	2.33K	3.8K	3.87K	2.56K
EBIT	-1.06M	-365K	0	-4.53M	-1.5M	-3.37M	-6.22M	-13.19M	-15.75M	-7.09M
Net Interest Income+	0	0	0	0	46.91K	-1.12K	0	-96.69K	-1.05M	-878.17K
Interest Income	12.36K	4.42K	0	0	48.06K	0	0	0	0	5.47K
Interest Expense	0	0	0	0	1.16K	1.12K	0	96.69K	1.05M	883.65K
Other Income/Expense	96K	121.34K	-12.44K	-363K	-99.49K	754.85K	0	-196.62K	-1.11M	-781.2K
Pretax Income+	-1.01M	-242K	-28.27M	-4.9M	-1.62M	-3.38M	-6.22M	-13.28M	-16.8M	-7.97M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-190K	0	0	0	-76.19K	-24.99K	-787K	-12.2K	22.41K	-3.26M
Effective Tax Rate %	0.81%	1%	1%	1%	0.95%	0.99%	0.87%	1%	1%	0.59%
Net Income+	-820K	-243K	-28.3M	-4.89M	-1.54M	-3.35M	-5.43M	-13.27M	-16.83M	-4.71M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	0.9%	0.7%	-115.46%	0.83%	0.68%	-1.17%	-0.62%	-1.44%	-0.27%	0.72%
Net Income (Continuing)	-820K	-242K	-28.27M	-4.9M	-1.54M	-3.35M	-5.43M	-13.27M	-16.83M	-4.71M
Discontinued Operations	190.41K	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.14	-0.04	-4.80	-0.62	-0.17	-0.32	-0.36	-0.60	-0.00	-0.12
EPS Growth %	0.89%	0.7%	-115.22%	0.87%	0.73%	-0.88%	-0.13%	-0.67%	1%	-
EPS (Basic)	-0.17	-0.04	-4.80	-0.62	-0.17	-0.32	-0.36	-0.60	-0.00	-0.12
Diluted Shares Outstanding	5.86M	5.86M	5.89M	7.91M	9.16M	10.35M	15.06M	22.26M	29.34M	39.49M
Basic Shares Outstanding	4.76M	5.86M	5.89M	7.91M	9.16M	10.35M	15.06M	22.26M	29.34M	39.49M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	5.37M	16.86M	48	758.75K	566.73K	6.99M	4.3M	5.2M	1.54M	3.68M
Cash & Short-Term Investments	5.13M	16.86M	0	627.56K	234.96K	6.89M	2.7M	4.05M	826.85K	1.56M
Cash Only	5.13M	0	0	627.56K	234.96K	6.89M	2.7M	4.05M	826.85K	1.56M
Short-Term Investments	0	16.86M	0	0	0	0	0	0	0	0
Accounts Receivable	12.15K	0	48	111.36K	326.22K	4.5K	883.43K	980.08K	580.94K	1.89M
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	126	-792	34	-1.49K	170.31K	0	0
Days Inventory Outstanding	-	-	-	209.68	-	0.95	-	16.37K	-	-
Other Current Assets	101.64K	0	0	85.46K	15	71.75K	1.49K	-170.31K	0	0
Total Non-Current Assets+	26.81M	0	0	1.1K	30.66K	104.64K	5.22K	7.22K	3.35K	2.04K
Property, Plant & Equipment	17.16M	0	0	1.1K	30.66K	104.64K	5.22K	7.22K	3.35K	2.04K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	616.71K	0	0	0	0	0	0	0	0	0
Intangible Assets	9.03M	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	0	0	0
Total Assets+	32.18M	0	0	759.86K	597.4K	7.09M	4.3M	5.2M	1.54M	3.68M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.05%	-1%	-	-	-0.21%	10.87%	-0.39%	0.21%	-0.7%	1.39%
Total Current Liabilities+	181.34K	0	0	426.72K	710.66K	1.71M	1.35M	7.26M	7.42M	9.23M
Accounts Payable	124.12K	141.79K	0	381.76K	593.72K	210.99K	517.67K	1.02M	6.13M	7.9M
Days Payables Outstanding	-	-	-	635.78K	36.29K	5.89K	77.98K	98.42K	578.57K	1000K
Short-Term Debt	0	0	0	0	0	34.14K	0	2.22M	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	16.95K	0	87.59K	-1.13K	-26.73K	1.43M	323.06K	1.29M	0	0
Current Ratio	29.62x	-	-	1.78x	0.80x	4.09x	3.17x	0.72x	0.21x	0.40x
Quick Ratio	29.62x	-	-	1.78x	0.80x	4.09x	3.18x	0.69x	0.21x	0.40x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	26.54K	64.61K	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	21.45K	64.61K	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	5.08K	0	0	0	0	0
Total Liabilities	181.34K	0	0	426.72K	737.2K	1.77M	1.35M	7.26M	7.42M	9.23M
Total Debt+	0	0	0	0	25.56K	98.76K	0	2.22M	0	0
Net Debt	-5.13M	0	0	-627.56K	-209.4K	-6.79M	-2.7M	-1.83M	-826.85K	-1.56M
Debt / Equity	-	-	-	-	-	0.02x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-1313.88x	-3680.63x	-	-135.36x	-14.90x	-8.14x
Total Equity+	32M	0	0	333.14K	-139.8K	5.32M	2.95M	-2.05M	-5.88M	-5.55M
Equity Growth %	-0.06%	-1%	-	-	-1.42%	39.05%	-0.45%	-1.7%	-1.86%	0.06%
Book Value per Share	5.46	-	-	0.04	-0.02	0.51	0.20	-0.09	-0.20	-0.14
Total Shareholders' Equity	32M	0	0	333.14K	-139.8K	5.32M	2.95M	-2.05M	-5.88M	-5.55M
Common Stock	95.12M	0	0	89.22M	0	0	123.98M	0	143.11M	0
Retained Earnings	-64.71M	0	0	-88.97M	-85.88M	-99.4M	-112.43M	-125.7M	-142.52M	-143.02M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-276.54K	0	0	82.12K	2.22M	12.82M	-11.01M	-7.74M	-11.31M	-11.47M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	-650.88K	-651.27K	-1.59M	-1.99M	-1.2M	-1.6M	-5.47M	-7.7M	-9.49M	-1.81M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	0.54%	-0%	-1.45%	-0.25%	0.4%	-0.33%	-2.42%	-0.41%	-0.23%	0.81%
Net Income	-820.17K	-241.93K	-28.27M	-4.9M	-1.62M	-3.38M	-6.22M	-13.28M	-16.83M	-7.97M
Depreciation & Amortization	0	0	0	218	5.98K	13.11K	2.33K	3.8K	3.87K	2.56K
Stock-Based Compensation	99.2K	18.37K	4.24K	50.53K	36.34K	544.39K	1.72M	1.27M	1.12M	734.99K
Deferred Taxes	0	0	0	-1.17K	146.58K	92.95K	-9.41K	250.34K	0	0
Other Non-Cash Items	-39.25K	0	26.63M	2.69M	42.84K	83K	61.72K	-84.16K	3.54M	1.8M
Working Capital Changes	109.34K	-427.71K	35.72K	176.81K	186.53K	1.04M	-1.02M	4.14M	2.67M	3.63M
Change in Receivables	0	0	0	0	-543	205.07K	27.38K	167.72K	440.26K	-90.4K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	-297.99K	0	2.8M	0
Cash from Investing+	-335.18K	-375.39K	0	-1.32K	-132.67K	-18.11K	-1.67K	-5.92K	0	-1.21K
Capital Expenditures	-406.05K	-375.39K	0	-1.32K	0	-6.94K	-1.67K	-5.92K	0	-1.21K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-334.72K	-373.6K	0	0	-132.67K	-21	0	0	0	0
Cash from Financing+	12.36K	4.42K	0	0	963.31K	7.83M	2.15M	9.32M	6.21M	2.66M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	963.31K	15.87K	725.51K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.06M	-1.03M	-1.59M	-1.99M	-1.2M	-1.61M	-5.47M	-7.7M	-9.49M	-1.81M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	0.75%	0.03%	-0.55%	-0.25%	0.4%	-0.34%	-2.4%	-0.41%	-0.23%	0.81%
FCF per Share	-0.18	-0.18	-0.27	-0.25	-0.13	-0.16	-0.36	-0.35	-0.32	-0.05
FCF Conversion (FCF/Net Income)	0.79x	2.68x	0.06x	0.41x	0.78x	0.48x	1.01x	0.58x	0.56x	0.38x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-2.49%	-	-	-1469.36%	-1595.28%	-129.51%	-131.39%	-2968.58%	-	-
Return on Invested Capital (ROIC)	-3.04%	-	-	-17587.12%	-	-	-1894.47%	-	-	-
Debt / Equity	-	-	-	-	-	0.02x	-	-	-	-
Interest Coverage	-	-	-	-	-1313.88x	-3680.63x	-	-135.36x	-14.90x	-8.14x
FCF Conversion	0.79x	2.68x	0.06x	0.41x	0.78x	0.48x	1.01x	0.58x	0.56x	0.38x

Frequently Asked Questions

Growth & Financials

OKYO Pharma Limited (OKYO) grew revenue by 0.0% over the past year. Growth has been modest.

OKYO Pharma Limited (OKYO) reported a net loss of $4.7M for fiscal year 2025.

Dividend & Returns

OKYO Pharma Limited (OKYO) had negative free cash flow of $1.8M in fiscal year 2025, likely due to heavy capital investments.